Iph4102-201
WebClinical Trial Name: IPH4102-201 / TELLOMAK study Clinical Trial Description: The trial is an open label, multi-cohort and multi-center phase II. It is designed to include a total of 3 … WebIPH4102-201: National Competent Authority: Italy - Italian Medicines Agency: Clinical Trial Type: EEA CTA: Trial Status: Ongoing: Date on which this record was first entered in the …
Iph4102-201
Did you know?
Web12 jul. 2024 · IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma Carrie Van Der … Web7 jun. 2024 · IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody that depletes KIR3DL2-expressing cells through antibody-dependent cell-cytotoxicity and …
WebProtocol: IPH4102-201: TELLOMAK: An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma Zhou, A. Medpace Clinical Research LLC, Innate Pharma SA 4/12/22 → 4/12/25 Project: Research project WebBrief Title: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma Official Title: TELLOMAK: T-cell Lymphoma Anti- KIR3DL2 Therapy . …
Web1 nov. 2014 · IPH4102 antitumor activity was mediated by antibody-dependent cell cytotoxicity and phagocytosis. IPH4102 improved survival and reduced tumor growth in … Web29 jan. 2024 · Innate Pharma : RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME MarketScreener INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME Fast Track designation is …
Web• Initiation of IPH4102 , an international, openTELLOMAK -label, multicohort Phase II - study evaluating the efficacy and safety of IPH4102 in patient populations larger expressing KIR3DL2, including peripheral T cell lymphoma (PTCL). TELLOMAK is planned to recruit up to 250 patients, with IPH4102 evaluated as a single agent in
Web13 okt. 2016 · IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed to trigger killing of CTCL cancer cells, an orphan disease. This group of rare cutaneous lymphomas of T... optus retention team contactWeb3 dec. 2024 · innate pharma announces updated results that support advancement of iph4102 in refractory sÉzary syndrome at the american society of hematology 2024 annual meeting differentiating... march 26, 2024 optus router firmware updateWeb1 aug. 2024 · IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its leukaemic form, Sézary syndrome. We aimed to assess the safety and activity of IPH4102 in cutaneous T-cell lymphoma. Methods portsmouth charitiesWeb15 jun. 2024 · About IPH4102: IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed for treatment of CTCL, an orphan disease. This group of rare cutaneous lymphomas of T... portsmouth centreWebBackground: IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its … optus router port forwardingWeb12 jul. 2024 · IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma Carrie Van Der Weyden , Martine Bagot , Paul Neeson , Phil K. Darcy & H. Miles Prince portsmouth cherbourg timetableWebRELATED APPLICATIONS. This application claims priority to U.S. Provisional Application No. 63/221,595 filed on Jul. 14, 2024, the content of which is hereby incorporated in its en optus router login